Bhore S.,AIMST University |
Preveena J.,AIMST University |
Kandasamy K.,Malaysian Forest Research Institute |
Kandasamy K.,Malaysian Biotechnology Corporation
Pharmacognosy Research | Year: 2013
Background: Resins and gums are used in traditional medicine and do have potential applications in pharmacy and medicine. Agarwood is the fragrant resinous wood, which is an important commodity from Aquilaria species and has been used as a sedative, analgesic, and digestive in traditional medicine. Endophytic bacteria are potentially important in producing pharmaceutical compounds found in the plants. Hence, it was important to understand which types of endophytic bacteria are associated with pharmaceutical agarwood-producing Aquilaria species. Objective: This study was undertaken to isolate and identify endophytic bacteria associated with agarwood-producing seven (7) Aquilaria species from Malaysia. Materials and Methods: Botanical samples of seven Aquilaria species were collected, and endophytic bacteria were isolated from surface-sterilized-tissue samples. The 16S rRNA gene fragments were amplified using PCR method, and endophytic bacterial isolates (EBIs) were identified based on 16S rRNA gene sequence similarity based method. Results: Culturable, 77 EBIs were analyzed, and results of 16S rRNA gene sequences analysis suggest that 18 different types of endophytic bacteria are associated with (seven) Aquilaria species. From 77 EBIs, majority (36.4%) of the isolates were of Bacillus pumilus. Conclusion: These findings indicate that agarwood-producing Aquilaria species are harboring 18 different types of culturable endophytic bacteria.
News Article | November 3, 2016
Bio adipic acid market size is likely to see significant growth as planned capacities come online over the next few years. Adipic acid market size was estimated at over 2.7 million tons in 2015 and is likely to exceed 4 million tons by 2023, growing at a CAGR of more than 4.5%. Adipic acid (ADA) market revenue was over USD 4.5 billion in 2015 and is likely to reach USD 7.4 billion by 2023. Nylon 6,6 was the largest application and accounted for more than 80% of the total volume in 2015. Polyurethane (PU) application is likely to be the fastest growing at gains of over 5.2% from 2016 to 2023. Request for an in-depth table of contents for this report @ https://www.gminsights.com/request-toc/upcoming/336 Asia Pacific adipic acid market size was estimated over 940 kilo tons in 2015 and is likely to witness highest gains of over 5% from 2016 to 2023. North America market is likely to be worth more than USD 2 billion by 2023 with expected gains of over 6%. The bio adipic acid market is still at the infancy stage as few companies have focused on research to commercialize production. Companies such as Verdezyne, DSM, BioAmeber, Ameris, Aemethis, Genomatica and Rennovia have successfully designed production technology to develop 100% bio ADA and would be commercializing the product over the coming years. Adipic acid market price trend is expected to remain stable between USD 1.6 to USD 1.9 per kilo. Increasing nylon 6.6 demand for durable application such as automobiles, textile, carpets, tire-cod and technical fibers is likely to drive bio adipic acid market. Industry participants are vying to manufacture 100% bio based nylon for industrial applications owing to stringent government policies over environmental concerns. Global nylon 6,6 market was estimated at over 1.3 million tons in 2013 and is likely to grow at a CAGR of over 4% from 2016 to 2023. In 2013, Rennovia announced successful completion of 100% bio based nylon 6,6. It is based on combination of Rennovia’s RENNLON bio based adipic acid and hexamethylenediamine (HMD). Rennovia is able to manufacture both the products through its patented chemical catalytic process technology. Rennovia bio adipic acid production is through anaerobic oxidation of glucose to obtain glucaric acid which further goes hydrooxygenation. Rennovia products are estimated to be cost competitive in comparison to petrochemical based products. The company is targeting to commercialize bio-based adipic acid market with an initial capacity of 135 kilo tons per annum by the end of 2018. Verdezyne is invested in research to develop bio ADA through fermentation technique using yeast microorganism which can utilize plant based oil, alkanes or sugar as feedstock. In 2013, the company announced collaboration with Malaysia’s biotechnology investment group, Biotechcorp (Malaysian Biotechnology Corporation). This would help the company to access Malaysia as the prime location to set up biotechnological production facility and is likely to procure local feedstock such as palm fatty acids and palm kernel oil distillates for manufacturing the end product. It is produced traditionally from petrochemical based feedstock such as cyclohexane, benzene and phenol. Cyclohexane based process accounts for over 90% of the production volume. Tight supply and volatile prices of cyclohexane is likely to affect industry profitability. Companies are focusing on green alternative routes to mitigate the risks as this could prove to be more beneficial in terms of cost and also would be entitled for government incentives in the form of subsidies & loan guarantees. With established companies such as Invista, BASF, Honeywell and PetroChina in the conventional space and a number of innovative start-ups developing sustainable technology, adipic acid market share may fragment over the next five years.
Markom M.,National University of Malaysia |
Hasan M.,University of Malaya |
Wan Daud W.R.,National University of Malaysia |
Anuar N.,National University of Malaysia |
And 2 more authors.
Separation Science and Technology | Year: 2011
Chemical profiles or fingerprints of polyphenolic compounds (condensed and hydrolyzable tannins) in various fractions of Phyllanthus niruri Linn extracted using supercritical carbon dioxide and various polar cosolvents, namely water, methanol, and ethanol are presented. Chemical analysis of the extracted fractions was undertaken using High Performance Liquid Chromatography (HPLC) with the in-house method. Good peak reproducibility of intra-day (R.S.D range 0.01-0.21 min) and inter-day (R.S.D range 0.5-0.8 min) was obtained for the detection of ellagitannins (hydrolyzable tannins) and flavonoids (condensed tannins). Fractions extracted using ethanol-water mixtures as cosolvent at 200 bar and 60°C exhibited an appealing behavior whereby non-polar compounds and flavonoids were able to be fractionated before the extraction of ellagitannins. Contents of three major ellagitannins, namely gallic acid (0.39-0.48% g/g), corilagin (2.42-3.00% g/g), and ellagic acid (5.94-6.48% g/g), were relatively higher compared to the commercial HEPAR-P™ standardized extract (0.21, 2.64, and 4.17% g/g, respectively). The study shows that the supercritical fluid extraction (SFE) method with the use of appropriate cosolvents is able to produce P. niruri fractions with improved yields and different chemical characteristic, which thus can be used as a rapid preparative tool for further downstream processing of plant samples. © Taylor & Francis Group, LLC.
Kamal N.,Malaysian Biotechnology Corporation |
Dir Z.C.,Malaysian Biotechnology Corporation
Journal of Commercial Biotechnology | Year: 2015
Advances in commercial application of biotechnology worldwide over the past two decades have led to the development of a bioeconomy, whereby substantial economic outputs are from the development and use of biological materials. Bioeconomy encompasses all industries and economic sectors based on the values implicit in biological materials that can be translated into new sources of income, environmental sustainability and social well-being. Malaysia, one of the most competitive biotechnology hubs in the Asia-Pacific region, has also taken critical early steps to coordinate and intensify national efforts to harness the potential of the bioeconomy. Most significantly, the Bioeconomy Transformation Programme (BTP) was launched in October 2012, making the country only the second in Asia, after China, and the first in ASEAN, to establish its own national bioeconomy initiative. The BTP is in line with the Government's objective to develop Malaysia into a high-income nation by the year 2020. The BTP aims to achieve this by focusing on bio-based industries in Malaysia, a sector that has been identified as having enormous potential to further develop the nation due to the abundance of natural resources available. With the introduction of the BTP, Malaysia is now unlocking even greater opportunities in the local and regional biotechnology industry, and enhancing the participation of the private sector. Through effective execution strategies from the Government and BiotechCorp, the biotechnology sector is now directly contributing towards efforts to drive Malaysia towards a high-income and knowledge-based economy by year 2020.
Bhore S.J.,AIMST University |
Komathi V.,AIMST University |
Kandasamy K.I.,Malaysian Forest Research Institute |
Kandasamy K.I.,Malaysian Biotechnology Corporation
Journal of Natural Science, Biology and Medicine | Year: 2013
Background: Nepenthes species are used in traditional medicines to treat various health ailments. However, we do not know which types of endophytic bacteria (EB) are associated with Nepenthes spp. Objective: The objective of this study was to isolate and to identify EB associated with Nepenthes spp. Materials and Methods: Surface-sterilized leaf and stem tissues from nine Nepenthes spp. collected from Peninsular Malaysia were used to isolate EB. Isolates were identified using the polymerase chain reaction-amplified 16S ribosomal DNA (rDNA) sequence similarity based method. Results: Cultivable, 96 isolates were analyzed; and the 16S rDNA sequences analysis suggest that diverse bacterial species are associated with Nepenthes spp. Majority (55.2%) of the isolates were from Bacillus genus, and Bacillus cereus was the most dominant (14.6%) among isolates. Conclusion: Nepenthes spp. do harbor a wide array of cultivable endophytic bacteria.
News Article | June 24, 2015
PHILADELPHIA: The Malaysian Biotech Corporation (BiotechCorp) says it remains focused on maintaining its bionexus companies' performance in the global market as Malaysia enters the third phase of the National Biotechnology Policy (NBP) next year. The NBP, introduced in 2005, aims to turn the biotechnology sector into one of the country's key economic drivers, with its implementation in three five-year phases. Remaining at the top is one of the biggest challenges faced by a bionexus company, BiotechCorp Board of Directors member Datuk Dr Abd Hapiz Abdullah said, adding the corporation has embarked on a monitoring and mentoring programme to help them sustain, if not grow, from their current level. "It's up to us and the Ministry of Science, Technology and Innovation to move forward with the bionexus companies and constantly remind them of the milestone that they need to achieve on a yearly basis. "With such programmes, every year we can see the development of our bionexus companies," he told Bernama on the sidelines of the International Bio Convention (BIO) 2015 held here on June 15-18. The event covered topics relevant to the biotechnology industry, including healthcare, intellectual property, environmental issues and business development. Hapiz said as having too many bionexus companies at one time is not a good idea, BiotechCorp prefers to focus on certain bionexus companies and make sure they achieve their ultimate target. "Each of the bionexus companies we brought to BIO 2015 has its own unique specialty that we feel can be promoted and commercialised in a good way. "So by meeting a lot of other players in the market, and with help from BiotechCorp and Larta Institute, the networking is established," he said. As some bionexus companies tend to lose confidence if they do not meet their growth target, they should carefully study the market they plan to venture into, he said. "Every Malaysian bionexus company must make sure that they come up with niche products, and they also have to know their own strengths," he added. BiotechCorp Chief Operating Officer Razwin Sulairee Hasnan Termizi echoed Hapiz's views, saying the Malaysian problem is fear of failure, and giving up when things don't go their way. "In this IT and biotechnology business, we don't punish startups. In the biotech industry, failure is the norm, but when you fall, you get up again," he said.- Bernama
News Article | June 4, 2015
KUALA LUMPUR: Malaysia is poised to become a key player in the global industrial biotechnology sector with the operation of the world's first integrated bio-methionine and thiochemicals facility worth RM2.1 billion. Owned by Koreas CJ CheilJedang (CJ) and Frances Arkema, the integrated manufacturing plant is located in Kertih Biopolymer Park (KBP), Terengganu. With the operation of the CJ-Arkema manufacturing facility, Malaysia is now the worlds first producer of green bio-methionine. The plant exported its first batch of essential amino acids to Indonesia in January 2015. Jointly promoted by the East Coast Economic Region Development Council and the Malaysian Biotechnology Corporation, the manufacturing facility is the single largest investment in Malaysias biotechnology sector to date. In a joint statement today, they said the project had a potential total investment of RM3 billion over a period of 10 years. In the longer term, the project is expected to generate a cumulative gross national income (GNI) of RM20.4 billion and create 2,500 green jobs for Malaysia by 2020. This includes 474 workers to be employed by CJ and Arkema, out of which 60% will consist of high-level technical and knowledge workers such as microbiologists, chemists, engineers and biotechnologists. CJ is a world leader in industrial biotechnology with innovations in fermentation and purification, while Arkema, which owns the proprietary platform technology, is a global chemical company and leading specialty chemicals producer. The plant in KBP is a platform for CJ, through its subsidiary CJ Bio Malaysia Sdn Bhd, to respond to the strong demand for methionine in Asia and China. This project also has the potential to develop local expertise in niche areas such as chemical engineering and industrial biotechnology, and provide an opportunity for collaborations with local universities and research institutions to become centres of excellence in biotechnology.-Bernama
News Article | March 1, 2015
Newswise — With a 600 million plus population and pharmaceutical market demand of USD21.3 billion in 2014, Association of Southeast Asian Nations (ASEAN) is poised to be the next economic powerhouse of Asia, through efforts such as the ASEAN Harmonization and Bioeconomy Transformation Programme. The ASEAN Harmonization is an effort pursued to create common standards in regulating the import and export of products across 10 member countries. In 2014, all 10 ASEAN member countries adopted the ASEAN Common Submission Dossier Template (CSDT) for Medical Devices, providing regulatory clarity for businesses to register their products in ASEAN. As the Chair of ASEAN in 2015, Malaysia is in a strong position to showcase the country’s unique value propositions as the gateway for businesses and investments into region at the BIO International Convention 2015. Participating for the 11th time, Malaysian Biotechnology Corporation (BiotechCorp), Malaysia’s lead agency in biotechnology aims to assert the country’s position as a strategic partner for the dynamic ASEAN market. With 78 participants in the Malaysian delegation hailing from government ministries, state governments, government agencies, funding institutions, and industry players, Malaysia is geared to showcase new offerings to global partners in the biomedical sector, including OECD GLP accredited services, world class infrastructure, and innovative healthcare products. The Malaysian Investment Development Authority (MIDA) and Malaysia External Trade Development Corporation (MATRADE) are among the various government agencies in attendance to showcase their strong support for biotechnology enterprises. “MOSTI is committed to providing the necessary assistance and facilitation to push Malaysia’s bioeconomy agenda and to keep the country competitive, innovative, and prosperous. We want Malaysia to be the gateway for the ASEAN market and to create a supportive, holistic, and integrated environment for bioeconomy to flourish in the region,” said Deputy Secretary General (Science) of the Ministry of Science, Technology & Innovation (MOSTI), Dr. Zulkifli bin Mohamed Hashim. The opening ceremony of the Malaysian Pavilion, on 16th June 2015, will begin with several announcements and exchange of documents highlighting the value propositions of Malaysia’s innovative biomedical industry. This is followed by the launch of the first Biotechnology Entrepreneurship Special Training (BeST) in USA, a specialized career-coaching programme designed to retain talent by connecting with Malaysian students studying in the USA. Under the Bioeconomy Accelerator Programme, BiotechCorp partnered with Larta Institute in Los Angeles to mentor Malaysian companies bringing in their products to USA and establish strategic partnerships to increase their product value. Cyberview, an emerging technology hub enabler, is also in attendance, acting as one of the sponsors of the Malaysian Pavilion and reception. Their value propositions include clean room laboratories that can accommodate high-value R&D and skilled workers “As one of the 12 mega biodiversity countries globally, Malaysia’s biodiversity and people diversity act as the encouragement for drug discovery and development programs to be undertaken in Malaysia. This is complemented by our comprehensive value chain in biotechnology that has attracted strong foreign players into our market,” said Malaysian Biotechnology Corporation (BiotechCorp) Chief Operating Officer, Razwin Sulairee Hasnan Termizi. Since the establishment of the National Biotechnology Policy in 2005, capacity building initiatives have been deployed for infrastructure, talent, financial, regulatory and branding. This 360 degrees approach relates to Malaysia’s aspiration for becoming the regional hub for biopharma investments, which ultimately contributes to the nation’s bioeconomy. BiotechCorp plays a key role to grow the bio-based industry in the region by offering attractive tax incentives for companies that qualify under the BioNexus status, awarded to qualified international and Malaysian biotechnology companies. With the aim to assist biotechnology companies in the U.S. that are looking at a regional hub in South East Asia, Malaysia opened its first BiotechCorp office in San Francisco on 12 June 2015. The country is also ranked fourth globally for Biotech Enterprise Support in the Scientific American Report and second in ASEAN for intellectual property protection in the IMD World Competitiveness Index Yearbook. This pro-patent environment is evident in the increase of up to 20% of patent application in Malaysia since 2014. As the biotechnology hub of South East Asia, Malaysia is offering more opportunities to investors through the availability of a full value chain for their businesses. More opportunities to be discovered, there is more to Malaysia. ### ABOUT BIOTECHCORP BiotechCorp is the lead development agency for the biotech industry in Malaysia and acts as a central contact point providing support, facilitation and advisory services for biotech and life sciences companies in Malaysia. BioNexus Status companies are international and Malaysian biotech companies that qualify for fiscal incentives, grants and guarantees administered by BiotechCorp. For further details, visit www.biotechcorp.com.my Bioeconomy Transformation Programme (BTP) is a platform provided by the Malaysian government for the private sector to channel and maximise commercial opportunities in bio-based industries. The BTP is designed as a Transformation Programme based on biotechnology’s potential to cut across various industries and transform Malaysia into a high income, inclusive and sustainable nation. Through the BTP, Bioeconomy will benefit the society and nation through breakthroughs in agricultural productivity, discoveries in healthcare and the adoption of sustainable industrial processes, having the effect of both enriching our society and nation through wealth creation besides securing our future. For further information, visit www.bioeconomy.my
News Article | July 27, 2015
KUALA LUMPUR, Malaysia--(BUSINESS WIRE)--IndiPharm (M) SDN BHD, a division of IndiPharm Inc. was awarded BioNexus status from the Malaysian Biotechnology Corporation (Biotechcorp) at BIO Philadelphia 2015, held on June 15-18, 2015. IndiPharm is a Clinical Development Organization, headquartered in the United States, with clinical and administrative operations in Malaysia and India. IndiPharm’s experienced management team, U.S.-based client services, strong global SOPs, well-trained medical professional staff, and deep understanding of local culture and regulatory systems, facilitates the delivery of high-quality clinical trials with lower costs, faster recruitment, and better quality outcomes. Biotechcorp is an agency under the purview of Ministry of Science, Technology and Innovation (MOSTI), and is owned by the Ministry of Finance Incorporated & Federal Lands Commissioner. It is governed by the National Bioeconomy Council and advised by the Biotechnology International Advisory Panel, both chaired by the Honorable Prime Minister of Malaysia. Biotechcorp is responsible for executing the objectives of the National Biotechnology Policy (NBP) by identifying value propositions in both R&D and commerce, and supporting these ventures via financial assistance and developmental services. BioNexus is a special status awarded to qualified international and Malaysian companies undertaking value-added biotechnology and/or life sciences activities. The status endows fiscal incentives, grants, and other guarantees to assist growth. Dato’ Dr. Mohd. Nazlee Kamal, Chief Executive Officer of Malaysian Biotechnology Corporation said, “We are very pleased for IndiPharm to join the list of BioNexus status companies, especially as they have chosen to establish their Asian headquarters in Malaysia. IndiPharm’s vast knowledge and expertise in clinical research services will undoubtedly enrich the growth of the biomedical sector in Malaysia, particularly in conducting clinical trials. We hope IndiPharm will take full advantage of the benefits that the BioNexus status offers to contribute to the healthcare community.” IndiPharm Inc. has relocated its Asian operations center to Kuala Lumpur in anticipation of future growth and client demands. Edward Brennan MD, President and CEO of IndiPharm Inc. stated, “IndiPharm is excited to have received the BioNexus status. Aside from the financial incentives provided, the Bionexus status grants IndiPharm access to clients and markets that otherwise would not be possible. We look forward to a long and successful relationship with Malaysian Biotechnology Corporation as we continue to expand our presence in Malaysia and Asia.”